Dudediligence.

AIM ImmunoTech Inc

AIMAMEX · Biological Products, (No Diagnostic Substances)
Write an idea

Fundamentals

Oldest to newest
Revenue, by quarter
$35,000Sep ’24$45,000Dec ’24$16,000Mar ’25$25,000Jun ’25$26,000Sep ’25$21,000Dec ’25$22,000Mar ’26$26,000Jun ’26
Net income, by quarter
−$3.7MSep ’24−$6.0MDec ’24−$3.7MMar ’25−$2.8MJun ’25−$3.3MSep ’25−$4.2MDec ’25−$3.0MMar ’26−$3.8MJun ’26
Fiscal years, by the month each ended
LineDec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue$135,000$141,000$202,000$170,000$88,000
Operating income−$18.8M−$19.9M−$31.9M−$19.8M−$11.7M
Net income−$19.1M−$19.4M−$29.0M−$17.3M−$14.0M
Operating cash flow−$14.0M−$16.1M−$21.3M−$14.9M−$11.0M
Free cash flow−$14.0M−$16.2Mnone on file−$14.9Mnone on file
Cash$32.1M$27.1M$5.4M$1.7M$3.0M
Debtnone on filenone on filenone on file$2.3M$4.5M
Shares outstanding48.0M48.1M49.1M655.3K3.1M